Abstract: The present disclosure concerns the use of oncolytic viruses for the treatment of cancer. In particular, the use of a herpes simplex virus, a vaccinia virus, or an adenovirus containing a gene encoding a PD-1 binding agent, such as a scFv polypeptide, to achieve a particular degree of oncolysis is described. In some embodiments, the oncolytic virus expressing the PD-1 binding agent is effective at inducing immune responses that kill cancer cells at distant sites from the primary tumor. An oncolytic virus can also be engineered to be less toxic or damaging to non-cancer cells by mutation or modification of gene products such that the alterations render the viruses better able to infect the host, less toxic, and/or better able to selectively infect cancer cells.

Abstract: The present invention relates to quinazolinone compounds, and methods of preparation of these compounds. The present invention also relates to pharmaceutical compositions comprising the quinazolinone compounds. The present invention provides methods of treating a cell proliferative disorder, such as a cancer, by administering to a subject in need thereof a therapeutically effective amount of a quinazolinone compound of the present invention.

Abstract: The present invention relates to quinazolinone compounds, and methods of preparation of these compounds. The present invention also relates to pharmaceutical compositions comprising the quinazolinone compounds.

Abstract: High-throughput methods are provided for quantitatively measuring the modulation of heat shock protein (HSP) expression in a cell by exposing the cell to at least one stress and measuring cellular stress responses. High-throughput methods for identifying modulators (activators or inhibitors) of HSP or HSF expression in a cell by treating the cell with an agent, such as a compound or composition, exposing the cell to a stress, and measuring responses of the cell to the stress in the presence or absence of the agent are also provided. Devices useful in performing high-throughput methods of the invention, and modulators identified using such methods, are also provided.

Abstract: The present invention provides methods of enhancing healing of wound associated with diabetes, comprising administering an effective amount of one or more of certain hydroxylamine derivatives to a subject in need thereof. In another aspect, the instant invention provides methods of treating or preventing peripheral nervous system neuropathies. Peripheral nervous system neuropathies may but need not be diabetic neuropathies, and may but need not be associated with a diabetic wound. The invention also provides pharmaceutical compositions comprising a certain hydroxylamine derivative or a pharmaceutically acceptable salt thereof, optionally in combination with one or more additional therapeutic agents. In certain compositions and methods, the additional therapeutic agent is a second hydroxylamine derivative or a pharmaceutically acceptable salt thereof.

Abstract: The present invention relates to quinazolinone compounds, and methods of preparation of these compounds. The present invention also relates to pharmaceutical compositions comprising the quinazolinone compounds.

Abstract: This invention relates to enhancing the bioavailability of pharmaceutically active agents. In particular, this invention relates to the use of lopinavir, its pharmaceutically acceptable equivalents, and derivatives thereof as P-glycoprotein inhibitors.